MIRM Stock Chart & Stats
$1256.12
$0.00(0.00%)
At close: 4:00 PM EDT
$1256.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$948.54 - $1,256.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$120.17B
Enterprise Value$5.37K
Total Cash (Recent Filing)$386.26M
Total Debt (Recent Filing)$323.78M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Jul 30, 2026EPS Estimate
-12.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.61
Shares Outstanding60,981,228
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.25
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,570.20Price Target Upside104.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $948.54 and its highest was $1256.12 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $120.17B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 3 days.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$234.139 earnings per share for the quarter, missing the consensus estimate of -$6.363 by -$227.776.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -12.69.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 60,981,228 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -$234.139 in its last earnings report, missing expectations of -$6.363. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2,570.20 (104.61% Upside)
$2,570.20 (104.61% Upside)
Blogger Sentiment
Bullish
MX:MIRM Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
29.07%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
MIRM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline and BD progress: solid Q1 sales growth (~42.9% YoY), an upward revision to full-year guidance, funded R&D investments, prioritized near-term regulatory catalysts (including a PDUFA on September 26, 2026), and a plan to scale the commercial team. These positives are tempered by a very large, one-time operating expense tied to the Bluejay acquisition that drove an unusually high quarterly operating charge ($761M of $949M), minimal Q1 operating cash flow (~$2M), elevated R&D spend, and remaining data and market-size uncertainties for some pipeline assets (e.g., FOP patient counts and certain subgroup signals in hepatitis delta). Management expects operating cash flow positivity next year and GAAP profitability by 2028, indicating confidence in the business model despite near-term accounting and investment-driven headwinds.View all MX:MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$2,570.20
▲(104.61% Upside)